CF PharmTech (02652) saw its shares climb nearly 9% in morning trading. As of press time, the stock was up 8.91%, trading at HK$6.665, with a turnover of HK$26.2328 million.
According to the latest data from the Hong Kong Stock Exchange, on October 6, Chairman and Chief Executive Officer Liang Wenqing increased his holdings by 19,300 shares of CF PharmTech at a price of HK$6.9216 per share, for a total amount of approximately HK$133,600. Following the increase, his latest shareholding stood at approximately 60.7165 million shares, representing an 18.74% stake.
It is worth noting that Chairman, Executive Director and Chief Executive Officer Dr. Liang Wenqing and the company's co-founder, Executive Director and Chief Scientific Officer Dr. Li Li recently made voluntary commitments to further extend the lock-up period on their shares by 6 months after the original lock-up period expires on October 7. The extended lock-up period runs from October 8, 2026 to April 7, 2027.
Comments